ID   PIEZ1_HUMAN             Reviewed;        2521 AA.
AC   Q92508; A6NHT9; A7E2B7; Q0KKZ9;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   28-JUN-2023, entry version 178.
DE   RecName: Full=Piezo-type mechanosensitive ion channel component 1;
DE   AltName: Full=Membrane protein induced by beta-amyloid treatment;
DE            Short=Mib;
DE   AltName: Full=Protein FAM38A;
GN   Name=PIEZO1; Synonyms=FAM38A, KIAA0233;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 432-2521, AND TISSUE SPECIFICITY.
RX   PubMed=16854388; DOI=10.1016/j.brainres.2006.06.050;
RA   Satoh K., Hata M., Takahara S., Tsuzaki H., Yokota H., Akatsu H.,
RA   Yamamoto T., Kosaka K., Yamada T.;
RT   "A novel membrane protein, encoded by the gene covering KIAA0233, is
RT   transcriptionally induced in senile plaque-associated astrocytes.";
RL   Brain Res. 1108:19-27(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 486-2521.
RC   TISSUE=Bone marrow;
RX   PubMed=9039502; DOI=10.1093/dnares/3.5.321;
RA   Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O.,
RA   Tanaka A., Kotani H., Miyajima N., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. VI. The
RT   coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of
RT   cDNA clones from cell line KG-1 and brain.";
RL   DNA Res. 3:321-329(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 486-2521.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 955-972; 1324-1334; 1548-1562 AND 1656-1671, VARIANTS
RP   DHS1 ARG-2225 AND HIS-2456, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=22529292; DOI=10.1182/blood-2012-04-422253;
RA   Zarychanski R., Schulz V.P., Houston B.L., Maksimova Y., Houston D.S.,
RA   Smith B., Rinehart J., Gallagher P.G.;
RT   "Mutations in the mechanotransduction protein PIEZO1 are associated with
RT   hereditary xerocytosis.";
RL   Blood 120:1908-1915(2012).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1391; SER-1646 AND THR-1854,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-2294.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1646, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20016066; DOI=10.1242/jcs.056424;
RA   McHugh B.J., Buttery R., Lad Y., Banks S., Haslett C., Sethi T.;
RT   "Integrin activation by Fam38A uses a novel mechanism of R-Ras targeting to
RT   the endoplasmic reticulum.";
RL   J. Cell Sci. 123:51-61(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1391 AND SER-1646, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-734; SER-758; SER-1391;
RP   SER-1396; SER-1636; SER-1646 AND THR-1854, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1646, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25119035; DOI=10.1038/nature13701;
RA   Li J., Hou B., Tumova S., Muraki K., Bruns A., Ludlow M.J., Sedo A.,
RA   Hyman A.J., McKeown L., Young R.S., Yuldasheva N.Y., Majeed Y.,
RA   Wilson L.A., Rode B., Bailey M.A., Kim H.R., Fu Z., Carter D.A., Bilton J.,
RA   Imrie H., Ajuh P., Dear T.N., Cubbon R.M., Kearney M.T., Prasad R.K.,
RA   Evans P.C., Ainscough J.F., Beech D.J.;
RT   "Piezo1 integration of vascular architecture with physiological force.";
RL   Nature 515:279-282(2014).
RN   [15]
RP   FUNCTION, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=29799007; DOI=10.1038/s41467-018-04436-w;
RA   Tsuchiya M., Hara Y., Okuda M., Itoh K., Nishioka R., Shiomi A., Nagao K.,
RA   Mori M., Mori Y., Ikenouchi J., Suzuki R., Tanaka M., Ohwada T., Aoki J.,
RA   Kanagawa M., Toda T., Nagata Y., Matsuda R., Takayama Y., Tominaga M.,
RA   Umeda M.;
RT   "Cell surface flip-flop of phosphatidylserine is critical for PIEZO1-
RT   mediated myotube formation.";
RL   Nat. Commun. 9:2049-2049(2018).
RN   [16]
RP   VARIANTS DHS1 SER-718; SER-782; GLN-808; LEU-1117; ASP-2003; VAL-2020;
RP   MET-2127; 2166-LYS--LYS-2169 DEL; HIS-2456 AND GLN-2488, CHARACTERIZATION
RP   OF VARIANTS DHS1 HIS-2456 AND GLN-2488, FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=23479567; DOI=10.1182/blood-2013-02-482489;
RA   Andolfo I., Alper S.L., De Franceschi L., Auriemma C., Russo R.,
RA   De Falco L., Vallefuoco F., Esposito M.R., Vandorpe D.H., Shmukler B.E.,
RA   Narayan R., Montanaro D., D'Armiento M., Vetro A., Limongelli I.,
RA   Zuffardi O., Glader B.E., Schrier S.L., Brugnara C., Stewart G.W.,
RA   Delaunay J., Iolascon A.;
RT   "Multiple clinical forms of dehydrated hereditary stomatocytosis arise from
RT   mutations in PIEZO1.";
RL   Blood 121:3925-3935(2013).
RN   [17]
RP   VARIANTS DHS1 PRO-1358; THR-2020; MET-2127 AND LEU-GLU-2496 INS,
RP   CHARACTERIZATION OF VARIANTS DHS1 PRO-1358; THR-2020; MET-2127;
RP   LEU-GLU-2496 INS; ARG-2225 AND HIS-2456, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=23695678; DOI=10.1038/ncomms2899;
RA   Albuisson J., Murthy S.E., Bandell M., Coste B., Louis-Dit-Picard H.,
RA   Mathur J., Feneant-Thibault M., Tertian G., de Jaureguiberry J.P.,
RA   Syfuss P.Y., Cahalan S., Garcon L., Toutain F., Simon Rohrlich P.,
RA   Delaunay J., Picard V., Jeunemaitre X., Patapoutian A.;
RT   "Dehydrated hereditary stomatocytosis linked to gain-of-function mutations
RT   in mechanically activated PIEZO1 ion channels.";
RL   Nat. Commun. 4:1884-1884(2013).
RN   [18]
RP   VARIANTS DHS1 ARG-2225 AND HIS-2456, CHARACTERIZATION OF VARIANTS DHS1
RP   ARG-2225 AND HIS-2456, AND MUTAGENESIS OF ARG-2456.
RX   PubMed=23487776; DOI=10.1073/pnas.1219777110;
RA   Bae C., Gnanasambandam R., Nicolai C., Sachs F., Gottlieb P.A.;
RT   "Xerocytosis is caused by mutations that alter the kinetics of the
RT   mechanosensitive channel PIEZO1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1162-1168(2013).
RN   [19]
RP   VARIANT DHS1 HIS-2456.
RX   PubMed=23973043; DOI=10.1016/j.bcmd.2013.07.015;
RA   Shmukler B.E., Vandorpe D.H., Rivera A., Auerbach M., Brugnara C.,
RA   Alper S.L.;
RT   "Dehydrated stomatocytic anemia due to the heterozygous mutation R2456H in
RT   the mechanosensitive cation channel PIEZO1: a case report.";
RL   Blood Cells Mol. Dis. 52:53-54(2014).
RN   [20]
RP   VARIANT DHS1 HIS-2456.
RX   PubMed=23581886; DOI=10.1111/cge.12147;
RA   Beneteau C., Thierry G., Blesson S., Le Vaillant C., Picard V., Bene M.C.,
RA   Eveillard M., Le Caignec C.;
RT   "Recurrent mutation in the PIEZO1 gene in two families of hereditary
RT   xerocytosis with fetal hydrops.";
RL   Clin. Genet. 85:293-295(2014).
RN   [21]
RP   INVOLVEMENT IN LMPHM6, AND VARIANTS LMPHM6 MET-939; LEU-2430; CYS-2456 AND
RP   LEU-2458.
RX   PubMed=26333996; DOI=10.1038/ncomms9085;
RA   Fotiou E., Martin-Almedina S., Simpson M.A., Lin S., Gordon K., Brice G.,
RA   Atton G., Jeffery I., Rees D.C., Mignot C., Vogt J., Homfray T.,
RA   Snyder M.P., Rockson S.G., Jeffery S., Mortimer P.S., Mansour S.,
RA   Ostergaard P.;
RT   "Novel mutations in PIEZO1 cause an autosomal recessive generalized
RT   lymphatic dysplasia with non-immune hydrops fetalis.";
RL   Nat. Commun. 6:8085-8085(2015).
RN   [22]
RP   POLYMORPHISM, INVOLVEMENT IN ER BLOOD GROUP SYSTEM, AND VARIANTS
RP   1763-TYR--GLU-2521 DEL; GLN-2245; LYS-2392; SER-2394; GLN-2407 AND
RP   LYS-2407.
RX   PubMed=36122374; DOI=10.1182/blood.2022016504;
RA   Karamatic Crew V., Tilley L.A., Satchwell T.J., AlSubhi S.A., Jones B.,
RA   Spring F.A., Walser P.J., Martins Freire C., Murciano N., Rotordam M.G.,
RA   Woestmann S.J., Hamed M., Alradwan R., AlKhrousey M., Skidmore I.,
RA   Lewis S., Hussain S., Jackson J., Latham T., Kilby M.D., Lester W.,
RA   Becker N., Rapedius M., Toye A.M., Thornton N.M.;
RT   "Missense mutations in PIEZO1, which encodes the Piezo1 mechanosensor
RT   protein, define Er red blood cell antigens.";
RL   Blood 141:135-146(2023).
CC   -!- FUNCTION: Pore-forming subunit of a mechanosensitive non-specific
CC       cation channel (PubMed:23479567, PubMed:23695678). Generates currents
CC       characterized by a linear current-voltage relationship that are
CC       sensitive to ruthenium red and gadolinium. Plays a key role in
CC       epithelial cell adhesion by maintaining integrin activation through R-
CC       Ras recruitment to the ER, most probably in its activated state, and
CC       subsequent stimulation of calpain signaling (PubMed:20016066). In the
CC       kidney, may contribute to the detection of intraluminal pressure
CC       changes and to urine flow sensing. Acts as shear-stress sensor that
CC       promotes endothelial cell organization and alignment in the direction
CC       of blood flow through calpain activation (PubMed:25119035). Plays a key
CC       role in blood vessel formation and vascular structure in both
CC       development and adult physiology (By similarity). Acts as sensor of
CC       phosphatidylserine (PS) flipping at the plasma membrane and governs
CC       morphogenesis of muscle cells. In myoblasts, flippase-mediated PS
CC       enrichment at the inner leaflet of plasma membrane triggers channel
CC       activation and Ca2+ influx followed by Rho GTPases signal transduction,
CC       leading to assembly of cortical actomyosin fibers and myotube
CC       formation. {ECO:0000250|UniProtKB:E2JF22, ECO:0000269|PubMed:20016066,
CC       ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:23695678,
CC       ECO:0000269|PubMed:25119035, ECO:0000269|PubMed:29799007}.
CC   -!- ACTIVITY REGULATION: Down-regulated by phosphatidylserines exposed on
CC       the cell surface. {ECO:0000269|PubMed:29799007}.
CC   -!- SUBUNIT: Homotrimer. Interacts with PKD2. Interacts with STOML3.
CC       {ECO:0000250|UniProtKB:E2JF22}.
CC   -!- INTERACTION:
CC       Q92508; P04155: TFF1; NbExp=5; IntAct=EBI-10986212, EBI-743871;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:20016066}; Multi-pass membrane protein. Endoplasmic
CC       reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000250|UniProtKB:Q0KL00}. Cell membrane
CC       {ECO:0000269|PubMed:22529292, ECO:0000269|PubMed:23479567}; Multi-pass
CC       membrane protein {ECO:0000305}. Cell projection, lamellipodium membrane
CC       {ECO:0000269|PubMed:25119035}. Cell membrane
CC       {ECO:0000250|UniProtKB:E2JF22}; Multi-pass membrane protein. Note=In
CC       erythrocytes, located in the plasma membrane (PubMed:22529292,
CC       PubMed:23479567). Accumulates at the leading apical lamellipodia of
CC       endothelial cells in response to shear stress (PubMed:25119035).
CC       Colocalizes with F-actin and MYH9 at the actomyosin cortex in
CC       myoblasts. {ECO:0000250|UniProtKB:E2JF22, ECO:0000269|PubMed:22529292,
CC       ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:25119035}.
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues. In normal brain,
CC       expressed exclusively in neurons, not in astrocytes. In Alzheimer
CC       disease brains, expressed in about half of the activated astrocytes
CC       located around classical senile plaques. In Parkinson disease
CC       substantia nigra, not detected in melanin-containing neurons nor in
CC       activated astrocytes. Expressed in erythrocytes (at protein level).
CC       Expressed in myoblasts (at protein level).
CC       {ECO:0000269|PubMed:16854388, ECO:0000269|PubMed:22529292,
CC       ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:29799007}.
CC   -!- DEVELOPMENTAL STAGE: At 17 weeks of gestation, strongly expressed in
CC       hepatic erythroblasts. At that stage, also expressed in fetal splenic
CC       plasma cells and in lymphatic vessel of fetal peritoneum. In vitro, up-
CC       regulated during the erythroid differentiation of CD34+ cells from
CC       healthy donors (at protein level). {ECO:0000269|PubMed:23479567}.
CC   -!- POLYMORPHISM: PIEZO1 is responsible for the Er blood group system (ER)
CC       [MIM:620207]. At least five antigens have been identified: Er(a),
CC       Er(b), Er(3), Er(4), and Er(5). The molecular basis of the Er(a)/Er(b)
CC       polymorphism is a single variation at position 2394; Gly-2394
CC       corresponds to Er(a) and Ser-2394 to Er(b), while the Er(3) antigen is
CC       recognized by antibodies produced by Er(a-b-) individuals. The Er(4)
CC       and Er(5) antigens are defined by Glu-2407 and Arg-2245, respectively.
CC       Alloantibodies against Er(4) and Er(5) are associated with hemolytic
CC       disease of the fetus and newborn. {ECO:0000269|PubMed:36122374}.
CC   -!- DISEASE: Dehydrated hereditary stomatocytosis 1 with or without
CC       pseudohyperkalemia and/or perinatal edema (DHS1) [MIM:194380]: An
CC       autosomal dominant hemolytic anemia characterized by primary
CC       erythrocyte dehydration. DHS erythrocytes exhibit decreased total
CC       cation and potassium content that are not accompanied by a proportional
CC       net gain of sodium and water. DHS patients typically exhibit mild to
CC       moderate compensated hemolytic anemia, with an increased erythrocyte
CC       mean corpuscular hemoglobin concentration and a decreased osmotic
CC       fragility, both of which reflect cellular dehydration. Patients may
CC       also show perinatal edema and pseudohyperkalemia due to loss of
CC       potassium from red cells stored at room temperature. A minor proportion
CC       of red cells appear as stomatocytes on blood films. Complications such
CC       as splenomegaly and cholelithiasis, resulting from increased red cell
CC       trapping in the spleen and elevated bilirubin levels, respectively, may
CC       occur. The course of DHS is frequently associated with iron overload,
CC       which may lead to hepatosiderosis. {ECO:0000269|PubMed:22529292,
CC       ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:23487776,
CC       ECO:0000269|PubMed:23581886, ECO:0000269|PubMed:23695678,
CC       ECO:0000269|PubMed:23973043}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. All disease-causing
CC       mutations characterized so far produce a gain-of-function phenotype,
CC       mutated channels exhibiting increased cation transport in erythroid
CC       cells, that could be due to slower channel inactivation rate compared
CC       to the wild-type protein.
CC   -!- DISEASE: Lymphatic malformation 6 (LMPHM6) [MIM:616843]: A form of
CC       primary lymphedema, a disease characterized by swelling of body parts
CC       due to developmental anomalies and functional defects of the lymphatic
CC       system. Patients with lymphedema may suffer from recurrent local
CC       infections. LMPHM6 is an autosomal recessive, severe form manifesting
CC       as generalized lymphatic dysplasia. It is characterized by uniform,
CC       widespread swelling of all segments of the body, with systemic
CC       involvement such as intestinal and/or pulmonary lymphangiectasia,
CC       pleural effusions, chylothoraces and/or pericardial effusions, and with
CC       a high incidence of non- immune hydrops fetalis.
CC       {ECO:0000269|PubMed:26333996}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Piezo comes from the Greek 'piesi' meaning pressure.
CC   -!- SIMILARITY: Belongs to the PIEZO (TC 1.A.75) family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC138028; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB161230; BAF03565.1; -; mRNA.
DR   EMBL; D87071; BAA13240.1; -; mRNA.
DR   EMBL; BC150271; AAI50272.1; -; mRNA.
DR   CCDS; CCDS54058.1; -.
DR   RefSeq; NP_001136336.2; NM_001142864.3.
DR   AlphaFoldDB; Q92508; -.
DR   SMR; Q92508; -.
DR   BioGRID; 115124; 57.
DR   IntAct; Q92508; 18.
DR   MINT; Q92508; -.
DR   STRING; 9606.ENSP00000301015; -.
DR   GuidetoPHARMACOLOGY; 2945; -.
DR   TCDB; 1.A.75.1.1; the mechanical nociceptor, piezo (piezo) family.
DR   GlyCosmos; Q92508; 2 sites, No reported glycans.
DR   GlyGen; Q92508; 3 sites.
DR   iPTMnet; Q92508; -.
DR   PhosphoSitePlus; Q92508; -.
DR   SwissPalm; Q92508; -.
DR   BioMuta; PIEZO1; -.
DR   DMDM; 317373533; -.
DR   EPD; Q92508; -.
DR   jPOST; Q92508; -.
DR   MassIVE; Q92508; -.
DR   MaxQB; Q92508; -.
DR   PaxDb; Q92508; -.
DR   PeptideAtlas; Q92508; -.
DR   ProteomicsDB; 75277; -.
DR   Antibodypedia; 44957; 205 antibodies from 24 providers.
DR   DNASU; 9780; -.
DR   Ensembl; ENST00000301015.14; ENSP00000301015.9; ENSG00000103335.22.
DR   GeneID; 9780; -.
DR   KEGG; hsa:9780; -.
DR   MANE-Select; ENST00000301015.14; ENSP00000301015.9; NM_001142864.4; NP_001136336.2.
DR   UCSC; uc010vpb.3; human.
DR   AGR; HGNC:28993; -.
DR   CTD; 9780; -.
DR   DisGeNET; 9780; -.
DR   GeneCards; PIEZO1; -.
DR   HGNC; HGNC:28993; PIEZO1.
DR   HPA; ENSG00000103335; Low tissue specificity.
DR   MalaCards; PIEZO1; -.
DR   MIM; 194380; phenotype.
DR   MIM; 611184; gene.
DR   MIM; 616843; phenotype.
DR   MIM; 620207; phenotype.
DR   neXtProt; NX_Q92508; -.
DR   OpenTargets; ENSG00000103335; -.
DR   Orphanet; 3202; Dehydrated hereditary stomatocytosis.
DR   VEuPathDB; HostDB:ENSG00000103335; -.
DR   eggNOG; KOG1893; Eukaryota.
DR   GeneTree; ENSGT00940000157348; -.
DR   HOGENOM; CLU_000512_0_0_1; -.
DR   InParanoid; Q92508; -.
DR   OMA; QRGNDIQ; -.
DR   OrthoDB; 5491808at2759; -.
DR   PhylomeDB; Q92508; -.
DR   TreeFam; TF314295; -.
DR   PathwayCommons; Q92508; -.
DR   SignaLink; Q92508; -.
DR   SIGNOR; Q92508; -.
DR   BioGRID-ORCS; 9780; 24 hits in 1164 CRISPR screens.
DR   ChiTaRS; PIEZO1; human.
DR   GenomeRNAi; 9780; -.
DR   Pharos; Q92508; Tchem.
DR   PRO; PR:Q92508; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q92508; protein.
DR   Bgee; ENSG00000103335; Expressed in muscle layer of sigmoid colon and 92 other tissues.
DR   ExpressionAtlas; Q92508; baseline and differential.
DR   Genevisible; Q92508; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0008381; F:mechanosensitive monoatomic ion channel activity; IBA:GO_Central.
DR   GO; GO:0005261; F:monoatomic cation channel activity; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IBA:GO_Central.
DR   GO; GO:0050982; P:detection of mechanical stimulus; IBA:GO_Central.
DR   GO; GO:0006812; P:monoatomic cation transport; ISS:UniProtKB.
DR   GO; GO:0033634; P:positive regulation of cell-cell adhesion mediated by integrin; IMP:UniProtKB.
DR   GO; GO:0033625; P:positive regulation of integrin activation; IMP:UniProtKB.
DR   GO; GO:0010831; P:positive regulation of myotube differentiation; IMP:UniProtKB.
DR   GO; GO:0042391; P:regulation of membrane potential; IBA:GO_Central.
DR   InterPro; IPR027272; Piezo.
DR   InterPro; IPR031805; Piezo_dom.
DR   InterPro; IPR031334; Piezo_RRas-bd_dom.
DR   PANTHER; PTHR13167:SF40; PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1; 1.
DR   PANTHER; PTHR13167; UNCHARACTERIZED; 1.
DR   Pfam; PF15917; PIEZO; 1.
DR   Pfam; PF12166; Piezo_RRas_bdg; 1.
PE   1: Evidence at protein level;
KW   Blood group antigen; Cell membrane; Cell projection; Coiled coil;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Hereditary hemolytic anemia;
KW   Ion channel; Ion transport; Membrane; Phosphoprotein; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..2521
FT                   /note="Piezo-type mechanosensitive ion channel component 1"
FT                   /id="PRO_0000186817"
FT   TRANSMEM        5..25
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        27..47
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        64..84
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        118..138
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        194..214
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        218..238
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        248..268
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        302..322
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        428..448
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        460..480
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        514..534
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        579..599
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        602..622
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        629..649
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        681..701
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        823..843
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        852..872
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        926..946
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        987..1007
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1043..1063
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1160..1180
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1184..1204
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1218..1240
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1247..1264
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1277..1297
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1678..1698
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1700..1720
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1734..1754
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1962..1982
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2003..2023
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2032..2052
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2061..2081
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2100..2122
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2129..2149
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2177..2197
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2198..2431
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:E2JF22"
FT   TRANSMEM        2432..2452
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          738..769
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1356..1402
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1462..1498
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1576..1630
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1811..1921
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1339..1368
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        746..760
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1356..1377
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1576..1598
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1605..1620
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1811..1826
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         734
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         758
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1396
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1636
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1646
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1854
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   CARBOHYD        295
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   DISULFID        2411..2415
FT                   /evidence="ECO:0000250|UniProtKB:E2JF22"
FT   VARIANT         718
FT                   /note="G -> S (in DHS1; dbSNP:rs755885744)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069822"
FT   VARIANT         782
FT                   /note="G -> S (in DHS1; dbSNP:rs200970763)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069823"
FT   VARIANT         808
FT                   /note="R -> Q (in DHS1; dbSNP:rs202103485)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069824"
FT   VARIANT         939
FT                   /note="L -> M (in LMPHM6; unknown pathological
FT                   significance; dbSNP:rs201226914)"
FT                   /evidence="ECO:0000269|PubMed:26333996"
FT                   /id="VAR_076407"
FT   VARIANT         1117
FT                   /note="S -> L (in DHS1; dbSNP:rs587777765)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069825"
FT   VARIANT         1358
FT                   /note="R -> P (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents; dbSNP:rs587776990)"
FT                   /evidence="ECO:0000269|PubMed:23695678"
FT                   /id="VAR_069826"
FT   VARIANT         1763..2521
FT                   /note="Missing (found in Er(a-b-) blood group phenotype;
FT                   dbSNP:rs72811487)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088145"
FT   VARIANT         2003
FT                   /note="A -> D (in DHS1)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069827"
FT   VARIANT         2020
FT                   /note="A -> T (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents; dbSNP:rs587776989)"
FT                   /evidence="ECO:0000269|PubMed:23695678"
FT                   /id="VAR_069828"
FT   VARIANT         2020
FT                   /note="A -> V (in DHS1; dbSNP:rs587777764)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069829"
FT   VARIANT         2127
FT                   /note="T -> M (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents; dbSNP:rs587776991)"
FT                   /evidence="ECO:0000269|PubMed:23479567,
FT                   ECO:0000269|PubMed:23695678"
FT                   /id="VAR_069830"
FT   VARIANT         2166..2169
FT                   /note="Missing (in DHS1)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069831"
FT   VARIANT         2225
FT                   /note="M -> R (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents; dbSNP:rs587776987)"
FT                   /evidence="ECO:0000269|PubMed:22529292,
FT                   ECO:0000269|PubMed:23487776, ECO:0000269|PubMed:23695678"
FT                   /id="VAR_069832"
FT   VARIANT         2245
FT                   /note="R -> Q (found in Er(5-) blood group phenotype that
FT                   is associated with hemolytic disease of the fetus and
FT                   newborn; dbSNP:rs2290901)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088146"
FT   VARIANT         2392
FT                   /note="E -> K (found in Er(a-b+) and Er(a-b-) blood group
FT                   phenotypes; dbSNP:rs528448732)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088147"
FT   VARIANT         2394
FT                   /note="G -> S (found in Er(a-b+) blood group phenotype;
FT                   dbSNP:rs201950081)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088148"
FT   VARIANT         2407
FT                   /note="E -> K (found in Er(4-) blood group phenotype that
FT                   is associated with hemolytic disease of the fetus and
FT                   newborn; dbSNP:rs200291894)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088149"
FT   VARIANT         2407
FT                   /note="E -> Q (found in Er(4-) blood group phenotype that
FT                   is associated with hemolytic disease of the fetus and
FT                   newborn; dbSNP:rs200291894)"
FT                   /evidence="ECO:0000269|PubMed:36122374"
FT                   /id="VAR_088150"
FT   VARIANT         2430
FT                   /note="P -> L (in LMPHM6; unknown pathological
FT                   significance; dbSNP:rs869025601)"
FT                   /evidence="ECO:0000269|PubMed:26333996"
FT                   /id="VAR_076408"
FT   VARIANT         2456
FT                   /note="R -> C (in LMPHM6; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26333996"
FT                   /id="VAR_076409"
FT   VARIANT         2456
FT                   /note="R -> H (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents; dbSNP:rs587776988)"
FT                   /evidence="ECO:0000269|PubMed:22529292,
FT                   ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:23487776,
FT                   ECO:0000269|PubMed:23581886, ECO:0000269|PubMed:23695678,
FT                   ECO:0000269|PubMed:23973043"
FT                   /id="VAR_069833"
FT   VARIANT         2458
FT                   /note="F -> L (in LMPHM6; unknown pathological
FT                   significance; dbSNP:rs577860843)"
FT                   /evidence="ECO:0000269|PubMed:26333996"
FT                   /id="VAR_076410"
FT   VARIANT         2488
FT                   /note="R -> Q (in DHS1; increased cation transport in
FT                   erythroid cells; dbSNP:rs749288233)"
FT                   /evidence="ECO:0000269|PubMed:23479567"
FT                   /id="VAR_069834"
FT   VARIANT         2496
FT                   /note="E -> ELE (in DHS1; gives rise to mechanically
FT                   activated currents that inactivate more slowly than
FT                   wild-type currents)"
FT                   /evidence="ECO:0000269|PubMed:23695678"
FT                   /id="VAR_069835"
FT   MUTAGEN         2456
FT                   /note="R->K: Does not inactivate the protein. gives rise to
FT                   mechanically activated currents that inactivate more slowly
FT                   than wild-type currents, suggesting it could shift the
FT                   channel kinetics from phasic to tonic."
FT                   /evidence="ECO:0000269|PubMed:23487776"
FT   CONFLICT        750
FT                   /note="Missing (in Ref. 3; BAA13240 and 4; AAI50272)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2521 AA;  286790 MW;  127A3DA3E7CBD2DD CRC64;
     MEPHVLGAVL YWLLLPCALL AACLLRFSGL SLVYLLFLLL LPWFPGPTRC GLQGHTGRLL
     RALLGLSLLF LVAHLALQIC LHIVPRLDQL LGPSCSRWET LSRHIGVTRL DLKDIPNAIR
     LVAPDLGILV VSSVCLGICG RLARNTRQSP HPRELDDDER DVDASPTAGL QEAATLAPTR
     RSRLAARFRV TAHWLLVAAG RVLAVTLLAL AGIAHPSALS SVYLLLFLAL CTWWACHFPI
     STRGFSRLCV AVGCFGAGHL ICLYCYQMPL AQALLPPAGI WARVLGLKDF VGPTNCSSPH
     ALVLNTGLDW PVYASPGVLL LLCYATASLR KLRAYRPSGQ RKEAAKGYEA RELELAELDQ
     WPQERESDQH VVPTAPDTEA DNCIVHELTG QSSVLRRPVR PKRAEPREAS PLHSLGHLIM
     DQSYVCALIA MMVWSITYHS WLTFVLLLWA CLIWTVRSRH QLAMLCSPCI LLYGMTLCCL
     RYVWAMDLRP ELPTTLGPVS LRQLGLEHTR YPCLDLGAML LYTLTFWLLL RQFVKEKLLK
     WAESPAALTE VTVADTEPTR TQTLLQSLGE LVKGVYAKYW IYVCAGMFIV VSFAGRLVVY
     KIVYMFLFLL CLTLFQVYYS LWRKLLKAFW WLVVAYTMLV LIAVYTFQFQ DFPAYWRNLT
     GFTDEQLGDL GLEQFSVSEL FSSILVPGFF LLACILQLHY FHRPFMQLTD MEHVSLPGTR
     LPRWAHRQDA VSGTPLLREE QQEHQQQQQE EEEEEEDSRD EGLGVATPHQ ATQVPEGAAK
     WGLVAERLLE LAAGFSDVLS RVQVFLRRLL ELHVFKLVAL YTVWVALKEV SVMNLLLVVL
     WAFALPYPRF RPMASCLSTV WTCVIIVCKM LYQLKVVNPQ EYSSNCTEPF PNSTNLLPTE
     ISQSLLYRGP VDPANWFGVR KGFPNLGYIQ NHLQVLLLLV FEAIVYRRQE HYRRQHQLAP
     LPAQAVFASG TRQQLDQDLL GCLKYFINFF FYKFGLEICF LMAVNVIGQR MNFLVTLHGC
     WLVAILTRRH RQAIARLWPN YCLFLALFLL YQYLLCLGMP PALCIDYPWR WSRAVPMNSA
     LIKWLYLPDF FRAPNSTNLI SDFLLLLCAS QQWQVFSAER TEEWQRMAGV NTDRLEPLRG
     EPNPVPNFIH CRSYLDMLKV AVFRYLFWLV LVVVFVTGAT RISIFGLGYL LACFYLLLFG
     TALLQRDTRA RLVLWDCLIL YNVTVIISKN MLSLLACVFV EQMQTGFCWV IQLFSLVCTV
     KGYYDPKEMM DRDQDCLLPV EEAGIIWDSV CFFFLLLQRR VFLSHYYLHV RADLQATALL
     ASRGFALYNA ANLKSIDFHR RIEEKSLAQL KRQMERIRAK QEKHRQGRVD RSRPQDTLGP
     KDPGLEPGPD SPGGSSPPRR QWWRPWLDHA TVIHSGDYFL FESDSEEEEE AVPEDPRPSA
     QSAFQLAYQA WVTNAQAVLR RRQQEQEQAR QEQAGQLPTG GGPSQEVEPA EGPEEAAAGR
     SHVVQRVLST AQFLWMLGQA LVDELTRWLQ EFTRHHGTMS DVLRAERYLL TQELLQGGEV
     HRGVLDQLYT SQAEATLPGP TEAPNAPSTV SSGLGAEEPL SSMTDDMGSP LSTGYHTRSG
     SEEAVTDPGE REAGASLYQG LMRTASELLL DRRLRIPELE EAELFAEGQG RALRLLRAVY
     QCVAAHSELL CYFIIILNHM VTASAGSLVL PVLVFLWAML SIPRPSKRFW MTAIVFTEIA
     VVVKYLFQFG FFPWNSHVVL RRYENKPYFP PRILGLEKTD GYIKYDLVQL MALFFHRSQL
     LCYGLWDHEE DSPSKEHDKS GEEEQGAEEG PGVPAATTED HIQVEARVGP TDGTPEPQVE
     LRPRDTRRIS LRFRRRKKEG PARKGAAAIE AEDREEEEGE EEKEAPTGRE KRPSRSGGRV
     RAAGRRLQGF CLSLAQGTYR PLRRFFHDIL HTKYRAATDV YALMFLADVV DFIIIIFGFW
     AFGKHSAATD ITSSLSDDQV PEAFLVMLLI QFSTMVVDRA LYLRKTVLGK LAFQVALVLA
     IHLWMFFILP AVTERMFNQN VVAQLWYFVK CIYFALSAYQ IRCGYPTRIL GNFLTKKYNH
     LNLFLFQGFR LVPFLVELRA VMDWVWTDTT LSLSSWMCVE DIYANIFIIK CSRETEKKYP
     QPKGQKKKKI VKYGMGGLII LFLIAIIWFP LLFMSLVRSV VGVVNQPIDV TVTLKLGGYE
     PLFTMSAQQP SIIPFTAQAY EELSRQFDPQ PLAMQFISQY SPEDIVTAQI EGSSGALWRI
     SPPSRAQMKR ELYNGTADIT LRFTWNFQRD LAKGGTVEYA NEKHMLALAP NSTARRQLAS
     LLEGTSDQSV VIPNLFPKYI RAPNGPEANP VKQLQPNEEA DYLGVRIQLR REQGAGATGF
     LEWWVIELQE CRTDCNLLPM VIFSDKVSPP SLGFLAGYGI MGLYVSIVLV IGKFVRGFFS
     EISHSIMFEE LPCVDRILKL CQDIFLVRET RELELEEELY AKLIFLYRSP ETMIKWTREK
     E
//
